| Source: |
| Type: |
| For many drugs, the half-life is the time it takes for half of the drug’s active substance to be eliminated from the bloodstream. In medicine, knowing a drug’s half-life helps in designing treatment regimens that reduce adverse effects. |
| 2188- | SK, | Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment |
| - | Review, | Var, | NA |
| 3041- | SK, | Promising Nanomedicines of Shikonin for Cancer Therapy |
| - | Review, | Var, | NA |
| 3040- | SK, | Pharmacological Properties of Shikonin – A Review of Literature since 2002 |
| - | Review, | Var, | NA | - | Review, | IBD, | NA | - | Review, | Stroke, | NA |
| 965- | SK, | Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 |
| 4742- | SSE, | Antitumor Effects of Selenium |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA | - | Review, | Sepsis, | NA |
| 5078- | SSE, | Rad, | Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer |
| - | Trial, | Pca, | NA |
| 5073- | SSE, | Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study |
| - | Trial, | Var, | NA |
| 5085- | SSE, | Intravenous Infusion of High Dose Selenite in End-Stage Cancer Patients: Analysis of Systemic Exposure to Selenite and Seleno-Metabolites |
| - | Review, | Var, | NA |
| 2084- | TQ, | Thymoquinone, as an anticancer molecule: from basic research to clinical investigation |
| - | Review, | Var, | NA |
| 3397- | TQ, | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 5904- | TV, | Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Diabetic, | NA | - | Review, | Obesity, | NA | - | Review, | AD, | NA | - | Review, | Arthritis, | NA |
| 3790- | UA, | Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools |
| 4864- | Uro, | Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4875- | Uro, | Impact of the Natural Compound Urolithin A on Health, Disease, and Aging |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | ostP, | NA | - | Review, | IBD, | NA |
| 4853- | Uro, | Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer |
| - | vitro+vivo, | PC, | MIA PaCa-2 | - | in-vitro, | NA, | PANC1 |
| 596- | VitC, | High-Dose Vitamin C in Advanced-Stage Cancer Patients |
| - | Review, | NA, | NA |
| 4087- | VitE, | Vitamin E and Alzheimer's disease: what do we know so far? |
| - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1109 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid